Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial

By afschroeder • June 5, 2026

Kim HR, Oliva M, Salas S, Wong DJ, Even C, Kim JW, Kang M, Wu SY, Lauche O, Ahn MJ, Yang MH, Lien MY, Metcalf R, Clatot F, McGrath M, Webster M, Assaf JD, Rivas AS, Bernsdorf M, Billan S, Kaczmar J, Grose D, Jankowska P, Jelinek MJ, Ciuleanu TE, Vieira C, Dutcus C, Okpara CE, Wang G, Bidadi B, Gumuscu B, Harrington K. Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial. Eur J Cancer. 2026 May 22;243:116824. doi: 10.1016/j.ejca.2026.116824. Epub ahead of print. PMID: 42241967.

Tags: Hematology/Oncology, lenvatinib, Multikinase inhibitor, PD-1 inhibitor, pembrolizumab, Publications, R/M HNSCC

Late Recognition of Glucose-6-Phosphate Dehydrogenase Deficiency in a 70-Year-Old Man: A Case Report

Huynh J, Eisenbud L, Gutierrez R, Chuang FL, Dichter D. Late Recognition of Glucose-6-Phosphate Dehydrogenase Deficiency in a 70-Year-Old Man: A Case Report. Cureus. 2026[...]

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators

Doroshow DB, Leal TA, Waqar SN, Borghaei H, Camidge DR, Dragnev KH, Edelman MJ, Gandara DR, Gerber DE, Gray JE, Hirsch FR, Husain H, Kozono[...]

Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium study

Nolin A, Brown MD, Thomas SM, Strickland KC, Bean S, Neff JL, Pothuri B, Moore KN, Mullen M, Clark LH, Konecny G, Jackson AL, Ko[...]